CLINICAL TRIAL

The oral Janus kinase/spleen tyrosine kinase inhibitor ASN 002 demonstrates efficacy and improves associated systemic inflammation in patients with moderate‐to‐severe atopic dermatitis: results from a randomized double‐blind placebo‐controlled study

Commentary or Editorial available

Plain Language Summary available

Article first published online: 06 May 2019
DOI: 10.1111/bjd.17932

Comment on this article

Summary

Background

ASN 002 is an oral dual inhibitor of Janus kinase and spleen tyrosine kinase, which are involved in the pathogenesis of atopic dermatitis ( AD ) through their regulatory role on T helper (Th)1, Th2 and Th17/Th22 pathways.

Objectives

The objectives of this study were to evaluate the efficacy, safety, pharmacokinetics and effects on systemic biomarkers of ASN 002 in patients with moderate‐to‐severe AD .

Methods A total of 36 patients with moderate‐to‐severe AD were randomized (3 : 1) to ASN 002 or placebo in the phase Ib study. Three dosage cohorts were studied over a 28‑day period (20 mg, 40 mg and 80 mg once daily).

Results

ASN 002 was superior to placebo for the proportion of patients achieving Eczema Area and Severity Index ( EASI ) 50 (20 mg 20%, P = 0·93; 40 mg 100%, P = 0·003; 80 mg 83%, P = 0·03; placebo 22%), EASI 75 (20 mg 0%, P = 0·27; 40 mg 71%, P = 0·06; 80 mg 33%, P = 0·65; placebo 22%) and in change from baseline in pruritus (20 mg −1·3 ± 2·1, P = 0·81; 40 mg −3·1 ± 2·7, P = 0·27; 80 mg −4·7 ± 2·1, P = 0·01; placebo −1·6 ± 1·8). Adverse events were generally mild and similar across all groups. ASN 002 showed dose‐dependent plasma exposure with low interpatient variability, significantly downregulated several serum biomarkers involved in Th1, Th2 and Th17/Th22 immunity, and decreased the atherosclerosis‐associated biomarker E selectin/ SELE .

Conclusions

In patients with moderate‐to‐severe AD , ASN 002 showed strong efficacy with rapid onset of action and associated improvements in systemic inflammation.

Read moreRead more (PDF)

Supporting Information

FilenameDescription
bjd17932-sup-0006-SupInfo.pptxPowerpoint S1 Journal Club Slide Set.
bjd17932-sup-0007-VideoS1.mp4Video S1 Author video.

Share this article

0

Favourite

Comments

If you want to submit a letter for publication rather than comment on an article please submit through Scholar One: https://mc.manuscriptcentral.com/bjd

There are no comments for this article yet.

Recent Tweets

@BrJDermatol

13 Nov 2019

Find out how changing immunosuppressive treatment practices have impacted SCC and BCC cancer risk in organ transplant recipients at https://t.co/wlvY9C1BnB #SCC #BCC #organtransplant #epidemiology https://t.co/tofI5FYhdu

@BrJDermatol

13 Nov 2019

RT The British Association of Dermatologists @HealthySkin4All: We are very excited to be planning the launch of a new open access journal, for which we are now looking for an Editor-in-Chief. Full details and information on how to apply for this role can be found here: https://t.co/42Fego0m99 @BrJDermatol @ced_wiley https://t.co/RAtLL76qpd

@BrJDermatol

13 Nov 2019

RT Dr Katie Farquhar @katiefarquhar: Very interesting article looking at skin cancer trends in transplant recipients from @BrJDermatol https://t.co/ia0PTvQCx9

@BrJDermatol

12 Nov 2019

Why has there been a significant reduction in the incidences of both SCC and BCC in organ transplant recipients over the past two decades? https://t.co/9LZepIh0V0 #SCC #BCC #organtransplant #epidemiology https://t.co/7mFJDPG3ch

@BrJDermatol

12 Nov 2019

RT The British Association of Dermatologists @HealthySkin4All: There is a need for more economic studies which look at the costs and effectiveness of two or more eczema treatments. These types of studies help inform how healthcare resources are used. https://t.co/jXK2mF2WQe @BrJDermatol @Wiley_Health @eczemasociety https://t.co/r90pWBEcRK

@BrJDermatol

11 Nov 2019

Join the discussion regarding the definition and clinical implications of palmoplantar pustulosis at https://t.co/rvMFifNM5l #psoriasis #commentary https://t.co/4BQRcTOq2S

Close